Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Intensity Therapeutics, Inc. ( (INTS) ).
On August 12, 2025, Intensity Therapeutics, Inc. amended its bylaws to change the quorum requirement for stockholder meetings from a majority to at least one-third of the voting power. This adjustment reflects a strategic move to facilitate decision-making processes within the company. Additionally, the company addressed a compliance issue with Nasdaq’s stockholders’ equity requirement. After raising $6.6 million through an At-the-Market offering in July 2025, Intensity Therapeutics reported sufficient stockholders’ equity in its quarterly report filed on August 7, 2025. Consequently, Nasdaq confirmed the company’s compliance with listing requirements, though it warned of potential delisting if future reports do not maintain compliance.
The most recent analyst rating on (INTS) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Intensity Therapeutics, Inc. stock, see the INTS Stock Forecast page.
Spark’s Take on INTS Stock
According to Spark, TipRanks’ AI Analyst, INTS is a Underperform.
Intensity Therapeutics faces significant challenges typical of a pre-revenue biotech firm, including negative financial metrics and bearish technical indicators. While recent corporate announcements about cancer treatment progress are promising, they do not outweigh the financial and technical difficulties. The overall score reflects these challenges, positioning the stock at the lower end of the scoring range.
To see Spark’s full report on INTS stock, click here.
More about Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. operates in the biotechnology industry, focusing on developing cancer therapies. The company is engaged in creating novel immune-based treatments aimed at improving the lives of patients with cancer.
Average Trading Volume: 3,671,619
Technical Sentiment Signal: Sell
For a thorough assessment of INTS stock, go to TipRanks’ Stock Analysis page.